New HPV vaccine attempts to go global

Article

Global News

GlaxoSmithKline is trying to obtain prequalification from the World Health Organization (WHO) for its new human papillomavirus (HPV) vaccine, Cervarix. Cervarix has already been approved in Europe, and is under review in the US.

If WHO grants the prequalification, then United Nations groups like UNICEF can distribute the vaccine to developing nations. Cervarix, similar to Merck's Gardasil, can substantially reduce the risk of cervical cancer, if given to girls before they become sexually active.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Michael Kruer, MD
Peter S. Jensen, MD
Robert Frenck, MD
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Smart infant monitors: a pediatrician’s guideLatest revision | Image Credit: © AdobeStock

Smart infant monitors: a pediatrician’s guide

Sunaina Kapoor, MD, MPH;Joseph M. Collaco, MD, PhD
March 6th 2025
Article

An overview of commercially available infant cardiorespiratory monitors and pulse oximeters in the home.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA approves neffy for anaphylaxis in children aged 4 years and olderLatest revision | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves neffy 1 mg for anaphylaxis in children aged 4 years and older

Joshua Fitch, Senior Editor
Published: March 6th 2025 | Updated: March 6th 2025
Article

The newly-approved indication is for children aged 4 years and older who weigh 33 < 66 lbs, expanding on the August 9, 2024 approval in children at least 66 lbs.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
The pediatric mental health crisis: A call to action for pediatricians | Image Credit: © Seventyfour - © Seventyfour - stock.adobe.com.

The pediatric mental health crisis: A call to action for pediatricians

Mike Hennessy Jr, President and CEO
March 5th 2025
Article

Mike Hennessy Jr, President and CEO of MJH Life Sciences kicks off our March Mental Health issue with a look into the ongoing pediatric mental health crisis.

FDA expands use of eculizumab to patients 6 years and up with generalized myasthenia gravis | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA expands use of eculizumab to patients 6 years and up with generalized myasthenia gravis

Joshua Fitch, Senior Editor
March 4th 2025
Article

First approved for PNH in 2007, the monoclonal antibody is now the first and only treatment for pediatric patients living with gMG.

© 2025 MJH Life Sciences

All rights reserved.